A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non–small cell lung cancer

KL Reckamp, K Krysan, JD Morrow, GL Milne… - Clinical cancer …, 2006 - AACR
Abstract Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …
被引用次数：139 相关文章

[引用][C] A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer

KL RECKAMP, K KRYSAN, JD MORROW… - Clinical cancer …, 2006 - pascal-francis.inist.fr
A phase I trial to determine the optimal biological dose of celecoxib when combined with
erlotinib in advanced non-small cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal …

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

KL Reckamp, K Krysan, JD Morrow… - … Cancer Research: an …, 2006 - europepmc.org
Purpose Overexpression of cyclooxygenase-2 (COX-2) activates extracellular signal-
regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth factor …

[引用][C] A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung Cancer

KL Reckamp, K Krysan, JD Morrow, GL Milne… - Clinical Cancer …, 2006 - cir.nii.ac.jp
A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with
Erlotinib in Advanced Non–Small Cell Lung Cancer | CiNii Research CiNii 国立情報学研究所 …

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer

KL Reckamp, K Krysan, JD Morrow… - … : an official journal …, 2006 - pubmed.ncbi.nlm.nih.gov
Purpose Overexpression of cyclooxygenase-2 (COX-2) activates extracellular signal-
regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth factor …

[引用][C] A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer

KL RECKAMP, K KRYSAN… - Clinical …, 2006 - American Association for Cancer …